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Abstract
Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a 
signifi cantly increased incidence of lung cancer and may infl uence treatment options and outcome. Impaired lung 
function confi rming COPD is an independent risk factor for lung cancer. Oxidative stress and infl ammation may 
be a key link between COPD and lung cancer, with numerous molecular markers being analysed to attempt to 
understand the pathway of lung cancer development. COPD negatively infl uences the ability to deliver radical 
treatment options, so attempts must be made to look for alternative methods of treating lung cancer, while aim-
ing to manage the underlying COPD. Detailed assessment and management plans utilising the multidisciplinary 
team must be made for all lung cancer patients with COPD to provide the best care possible.
Journal of Comorbidity 2011;1:45–50
Keywords: chronic obstructive pulmonary disease (COPD), comorbidity, infl ammation, lung cancer, oxidative stress, 
pulmonary
Correspondence: Dr Derek Grose, MRCP, FRCR, Consultant 
Clinical Oncologist, Beatson West of Scotland Cancer Centre, 1053 
Great Western Rd, Glasgow G12 0YN, Scotland, UK. 
Tel.: +44 (0)141 301 7070;
E-mail: Derek.grose@ggc.scot.nhs.uk
Received: Nov 1, 2011; Accepted: Nov 28, 2011; Published: Dec 27, 2011
Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterized, according to the Global Initiative for Chronic 
Obstructive Lung Disease® (GOLD), as “chronic airfl ow 
limitation and a range of pathological changes in the lung, 
some signifi cant extrapulmonary effects, and important 
comorbidities which may contribute to the severity of the 
disease in individual patients” [1, 2]. The airfl ow limita-
tion characterizing COPD is not fully reversible, is usually 
progressive, and results from an abnormal infl ammatory 
response to noxious particles or gases in the lungs [2, 3]. 
A preventable and treatable disease, COPD is a costly 
burden to healthcare systems as well as an important cause 
of morbidity and mortality [3]. Worldwide, approximately 
10% of adults have COPD graded as moderate severity 
or worse [forced expiratory volume in 1 second (FEV
1
) 
<80%] [4], and COPD is an increasing problem in the 
developing world [5]. Although the risk of COPD is 
increased by exposure to air pollution, occupational haz-
ards, and infections, the single most important risk factor 
is cigarette smoking [3]. It therefore comes as no surprise 
that COPD is a commonly encountered comorbidity in 
patients with lung cancer [6–8]. Indeed, recent studies 
have shown that COPD affects 50–90% of lung cancer 
patients [8, 9]. Moreover, patients with COPD are three 
to four times more likely to develop lung cancer compared 
with smokers with normal lung function [10, 11], and lung 
cancer is a major cause of mortality in COPD patients, 
particularly in those with mild or moderate disease [12]. 
However, it must be noted, that at least some of the asso-
ciation may be related to ‘detection bias’ in that subclinical 
COPD may be diagnosed during pre-assessment for lung 
surgery or radiotherapy in a lung cancer patient.
COPD, in addition to many other comorbidities, 
has a signifi cant impact upon the ability to deliver 
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recommended treatment and consequently on outcome 
[13–17]. This is not only the case in radical treatment 
delivery aiming for cure but also in (the far more com-
mon) situations where palliative chemotherapy and/
or radiotherapy are being considered to improve both 
duration and quality of life.
COPD has long been recognized as an indicator of a 
high risk of complications after lung resection [18, 19]. 
For example, in patients with lung cancer and COPD 
who undergo surgery, postoperative pneumonia and tra-
cheostomy are more frequent in patients with COPD 
than in those without [20]. Moreover, the presence of 
COPD signifi cantly increases the risk of cardiac dys-
rhythmias, specifi cally supraventricular tachycardia [21]. 
Mortality rates are signifi cantly higher in lung cancer 
patients who have postoperative pulmonary complica-
tions than in those who do not [18], and in comparison 
with lung cancer patients who do not have COPD, those 
with COPD have poorer long-term survival as a result 
of respiratory insuffi ciency [22], a higher rate of recur-
rence of the lung cancer [20], and poorer survival after 
surgery [23]. The clear link between the severity of the 
COPD and survival confi rms COPD as a key prognostic 
factor in patients with lung cancer [23, 24].
Pathophysiology
Impaired lung function, as indicated by a reduced base-
line FEV
1
 and reduced FEV
1
 to forced vital capacity 
(FVC) ratio – that is, COPD – has been shown in several 
studies to be an independent risk factor for lung cancer 
[e.g. 8, 25, 26] (Figure 1). The risk of lung cancer is at 
least twice as high [11, 27, 28] and may be up to six times 
as high [8] in individuals with COPD as in those with-
out COPD. More than 80% of cases of lung cancer and 
COPD can be attributed to exposure to cigarette smoke, 
which causes oxidative stress and infl ammation in the 
lung [29, 30]. Oxidative stress and infl ammation in turn 
lead to epigenetic alterations mediated by chromatin-
modifying enzymes (histone acetyltransferases, deacety-
lases, methyltransferases, and demethylases) – which have 
key roles in functions such as expression of infl ammatory 
mediators, cell-cycle arrest, apoptosis, responses to anti-
oxidants and stress, and replication, recombination, and 
repair of DNA – and the resulting chromatin remod-
elling is likely to be at the heart of the link between 
COPD and lung cancer [29]. 
At the molecular biological level, there is emerging 
evidence that COPD and lung cancer are linked by a 
faulty infl ammatory-repair response to cigarette smoke 
or other airborne pollutants [30]. The increased release 
of growth factors and matrix metalloproteinases result-
ing from an exaggerated infl ammatory response leads 
to lung matrix remodelling, including an epithelial to 
mesenchymal transition – a type of malignant transfor-
mation seen in several cancers as well as lung cancer, 
but also seen in COPD [8, 9, 30, 31]. Factors participat-
ing in lung matrix remodelling include infl ammatory 
cytokines such as interleukin 6 [8, 9, 30, 31] and those 
involved in oxidative stress and ineffective DNA repair 
[32]. Deregulation of the phosphatidylinositol 3-kinase 
pathway has been shown to be an early event in the 
development of lung cancer [33], and altered signalling 
via the epidermal growth factor receptor may lead to 
the development of lung cancer in patients with COPD 
[34].
In efforts to explain why lung cancer develops in 
only 10–15% of smokers, much recent work has focused 
on the roles of an aberrant infl ammatory response and 
genetic susceptibility in lung carcinogenesis and COPD 
[29, 30, 35–39]. Genetic studies have strongly impli-
cated variation in the 15q chromosomal region, where 
the nicotinic acetylcholine receptor is encoded [40–47], 
and the 5p region, where genes encode factors with roles 
in telomerase production, carcinogenesis, and apoptosis 
[42].
Management
Recommendations and guidelines developed in accor-
dance with the American College of Physicians (ACP), 
American College of Chest Physicians (ACCP), 
American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) exist for the management 
of stable COPD [1, 48, 49]. The guidelines proposed 
by these colleges and societies are summarized in 
Table 1.
Factors strongly linked to COPD – lung function 
and performance status – determine whether lung 
cancer patients with COPD are able to undergo cura-
tive surgery or radical radiotherapy [50]. Adequate lung 
function (evaluated by spirometry) is a prerequisite for 
potentially curative surgery, and a pre-operative FEV
1
 
>1.5 L in patients undergoing a lobectomy or >2.0 L in 
those undergoing a pneumonectomy is associated with 
a mortality rate <5% [50]. However, it is essential to 
evaluate the percentage predicted FEV
1
 as well as the 
absolute value. In borderline cases, cardiopulmonary 
exercise testing can be useful in decision making [51]. 
Although mild COPD does not necessarily preclude 
defi nitive treatment of lung cancer, severe COPD may, 
for example, make the lung cancer inoperable because 
the patient has low cardiopulmonary reserve [20, 22] 
and an increased risk of perioperative pulmonary com-
plications [19, 21, 22]. This may, in part, be partially 
due to severely impaired endothelial repair mechanisms 
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[52]. These observations may explain why lung cancer 
patients have been more likely to receive non-surgical 
treatment (i.e. radiotherapy rather than surgery) if they 
have signifi cant COPD [7, 53]. Indeed, a report from 
Japan concluded that the main therapeutic goal for lung 
cancer patients with COPD should be to achieve quality 
of life improvement through palliative care [54]. How-
ever, one study suggests that lobectomy for lung cancer 
can achieve a better outcome in COPD patients than 
in non-COPD patients [55]. Furthermore, given the 
limitations and poor outcomes of non-surgical treat-
ment for COPD, more inclusive surgical criteria have 
been suggested [56], and alternative surgical techniques 
(anatomical segmentectomy, lobectomy by video-
assisted thoracoscopic surgery) explored [57]. Quality 
of life after lobectomy has been shown to be similar in 
COPD and non-COPD patients [58], and recently, use 
of bronchodilators, such as tiotropium, has been shown 
to improve surgical outcomes in patients with COPD 
and lung cancer [34, 59]. 
One encouraging scenario is the emergence of 
non-surgical alternatives for radical treatment of 
localized curable lung cancers in the form of mod-
ern radio therapy techniques, such as stereotactic body 
radiotherapy (SBRT). A number of studies have been 
published indicating excellent outcome in medically 
inoperable, otherwise resectable, lung cancer patients 
[60, 61]. It is noteworthy that even relatively severe 
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Figure 1 Pathophysiology of chronic obstructive pulmonary disease (COPD) and lung cancer. FEV
1
, forced expiratory volume in 1 second; FVC, 
forced vital capacity.
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COPD appears to have little effect on the outcome of 
such patients [62].
It is important to consider that the vast majority of 
lung cancer patients will present with locally advanced 
or metastatic disease, making cure very highly unlikely. In 
these patients, the commonest treatment is for palliative 
chemotherapy or radiotherapy. There is very little in the 
literature indicating a direct impact of COPD upon deliv-
ery of chemotherapy. However, COPD often negatively 
impacts upon performance status, which is closely linked 
to both tolerance and benefi t of palliative chemotherapy 
[63–65]. 
An important aspect of treatment of COPD and lung 
cancer concerns possible ‘spillover’ of infl ammatory 
mediators from the lung, which may lead to extrapul-
monary effects [66]. The ‘spillage’ can be treated with 
anti-infl ammatory agents (preferably inhaled, to avoid risk 
of systemic side-effects), to suppress pulmonary infl am-
mation. Examples include corticosteroids, long-acting β
2
 
agonists, and theophylline. Infl ammation associated with 
COPD may also be reduced by treatment with statins, 
angiotensin-converting enzyme inhibitors, or peroxisome 
proliferator-activated agonists [66]. Statins may be par-
ticularly benefi cial in patients with COPD because they 
suppress infl ammatory and matrix remodelling pathways, 
and they target both pulmonary and systemic infl am-
mation [31]. Treatments of the future may target matrix 
metalloproteinases [67] or the arylhydrocarbon receptor 
[68], or may consist of cell-based therapies using embry-
onic or adult stem cells [69]. 
Concluding remarks
Both COPD and lung cancer are rising worldwide in 
incidence and are signifi cant causes of morbidity and 
mortality, imposing a signifi cant burden on healthcare 
systems throughout both the developed and develop-
ing world. Nearly 40,000 new cases of lung cancer were 
reported in 2007 in the UK alone [70]. Furthermore, 
with the increase in smoking and increasing life expec-
tancy in the developing world, lung cancer is likely to 
only increase as a burden on the health services of devel-
oping countries in the future.
It is clear that COPD and lung cancer are closely 
linked entities with each having a signifi cant detrimental 
impact upon the other. This ranges from increased inci-
dence of lung cancer in patients with COPD, through to 
inability to deliver radical therapy and increased compli-
cations following surgery. 
It is essential that a careful and complete evaluation 
of all comorbidity, but in particular COPD, should 
be made in all patients with lung cancer to enable an 
optimal individualized treatment plan [14, 71] coor-
dinated by the multidisciplinary clinical care team 
[50].
It is only by addressing this signifi cant challenge of 
carefully assessing and treating patients with overlapping 
comorbid conditions that we will be able to develop 
individualized treatments for patients and improve upon 
the poor outlook for the majority of our lung cancer 
patients.
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Table 1 Guideline recommendations for the management of chronic obstructive pulmonary disease (COPD) [1, 48, 49].
Recommendation Guideline
Stable COPD patients with respiratory symptoms and FEV1. 
1
 between 60 and 80% predicted may receive treatment with 
inhaled bronchodilators 
ACP, ACCP, 
ATS, ERS
Symptomatic patients with stable COPD and FEV2. 
1
 <60% predicted may receive treatment with inhaled bronchodilators, 
monotherapy using either long-acting, inhaled β agonists or long-acting, inhaled anticholinergics or combination inhaled 
therapies using long-acting β agonists, long-acting anticholinergics, or corticosteroids 
ACP, ACCP, 
ATS, ERS
Pulmonary rehabilitation should be prescribed for symptomatic patients with an FEV3. 
1
 <50% predicted, and considered for 
symptomatic or exercise-limited patients with an FEV
1
 >50% predicted 
ACP, ACCP, 
ATS, ERS
For COPD patients with severe resting hypoxaemia (PaO4. 
2
 ≤55 mm Hg or SpO
2
 ≤88%), continuous oxygen therapy is 
recommended 
ACP, ACCP, 
ATS, ERS
The GOLD committee broadly agrees with the above recommendations but advocates the use of inhaled 5. 
glucocorticosteroids and bronchodilators for symptomatic COPD patients with FEV
1
 <50% predicted and repeated 
exacerbations
GOLD
ACCP, American College of Chest Physicians; ACP, American College of Physicians; ATS, American Thoracic Society; ERS, European Respiratory 
Society; FEV
1
, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease®; PaO
2
, partial pressure of oxygen 
in arterial blood; SpO
2, 
saturation of peripheral oxygen.
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